Suchergebnisse - "Weinreich, David M"

PubPharm (30)

1

Garetosmab in fibrodysplasia ossificans progressiva : a randomized, double-blind, placebo-controlled phase 2 trial

enthalten in: Nature medicine | 2023

von Di Rocco, M. | Forleo-Neto, E. | Pignolo, R. | +33

2

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

enthalten in: Scientific reports | 2023

von Li, D. | Xu, M. | Hooper, A. | +9

3

Dupilumab in patients with prurigo nodularis : two randomized, double-blind, placebo-controlled phase 3 trials

enthalten in: Nature medicine | 2023

von Yosipovitch, G. | Mollanazar, N. | Ständer, S. | +14

4

REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit

enthalten in: The Journal of allergy and clinical immunology | 2022

von de Blay, F. | Gherasim, A. | Domis, N. | +15

5

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

enthalten in: The Journal of infectious diseases | 2022

von Somersan-Karakaya, S. | Mylonakis, E. | Menon, V. | +31

6

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

enthalten in: mBio | 2022

von Hooper, A. | Somersan-Karakaya, S. | McCarthy, S. | +12

7

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial

enthalten in: Nature medicine | 2022

von Gogishvili, M. | Melkadze, T. | Makharadze, T. | +23

8

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Infectious diseases | 2022

von Herman, G. | O'Brien, M. | Forleo-Neto, E. | +127

CommentIn: Lancet Infect Dis. 2022 Oct;22(10):1400-1401. - PMID 35803288

9

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022

von Isa, F. | Forleo-Neto, E. | Meyer, J. | +28

10

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2022

von Paller, A. | Simpson, E. | Siegfried, E. | +56

CommentIn: Lancet. 2022 Sep 17;400(10356):867-869. - PMID 36116468